1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Tetracaine hydrochloride, Neomycin sulfate, Isoflupredone acetate Topical Ointment
Trade Name: Tritop (R) Topical Ointment
Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against
Intended Use: Veterinary product used as antibiotic agent

Details of the Supplier of the Safety Data Sheet

Zoetis Inc.
100 Campus Drive, P.O. Box 651
Florham Park, New Jersey 07932 (USA)
Rocky Mountain Poison Control Center Phone: 1-866-531-8896
Product Support/Technical Services Phone: 1-800-366-5288

Emergency telephone number: CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: VMIPSRrecords@zoetis.com

Zoetis Belgium S.A.
Mercuriusstraat 20
1930 Zaventem
Belgium

Emergency telephone number: International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Appearance: Clear, colorless ointment

Classification of the Substance or Mixture
GHS - Classification
- Respiratory Sensitization: Category 1
- Skin Sensitization: Category 1
- Reproductive Toxicity: Category 2
- Carcinogenicity: Category 1B

EU Classification:
- EU Indication of danger: Carcinogenic: Category 2
  Toxic
EU Symbol: T
EU Risk Phrases:
- R45 - May cause cancer.

Label Elements

Signal Word: Danger
Hazard Statements:
- H334 - May cause allergy or asthma symptoms or breathing difficulties if inhaled
- H317 - May cause an allergic skin reaction
- H361 - Suspected of damaging fertility or the unborn child
- H351 - Suspected of causing cancer

Revision date: 25-Apr-2014
Version: 2.0
Page 1 of 10
Precautionary Statements:
P261 - Avoid breathing dust/fume/gas/mist/vapors/spray
P284 - Wear respiratory protection
P272 - Contaminated work clothing should not be allowed out of the workplace
P280 - Wear protective gloves/protective clothing/eye protection/face protection
P201 - Obtain special instructions before use
P202 - Do not handle until all safety precautions have been read and understood
P304 + P340 - IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P342 + P311 - If experiencing respiratory symptoms: Call a POISON CENTRE or doctor/physician
P333 + P313 - If skin irritation or rash occurs: Get medical advice/attention
P362 - Take off contaminated clothing and wash before reuse
P308 + P313 - IF exposed or concerned: Get medical advice/advice
P405 - Store locked up
P501 - Dispose of contents/container in accordance with all local and national regulations

Other Hazards
Short Term: May be harmful if swallowed. May cause eye, skin and respiratory tract irritation

Known Clinical Effects: The most common adverse effects reported with clinical use were diarrhea, nausea, rash, and vomiting. Individuals sensitive to this material or other materials in its chemical class may develop allergic reactions. Clinical use of this drug has caused kidney dysfunction, effects on hearing, decrease in blood pressure (hypotension), nervousness, blurred vision, anxiety, drowsiness, convulsion, respiratory arrest.

Australian Hazard Classification (NOHSC):

Note: This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

### 3. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>EU Classification</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>White Petrolatum</td>
<td>8009-03-8</td>
<td>232-373-2</td>
<td>Carc. Cat. 2; R45</td>
<td>Car. 1B, H350</td>
<td>1</td>
</tr>
<tr>
<td>Mineral oil</td>
<td>8012-95-1</td>
<td>232-384-2</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>1</td>
</tr>
<tr>
<td>Tetracaine Hydrochloride</td>
<td>136-47-0</td>
<td>205-248-5</td>
<td>T; R25</td>
<td>Acute Tox. Cat 3</td>
<td>0.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(H301)</td>
<td></td>
</tr>
</tbody>
</table>
3. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>EU Classification</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neomycin Sulfate</td>
<td>1405-10-3</td>
<td>215-773-1</td>
<td>Xn;R42/43 Repr.Cat.3;R63</td>
<td>Resp. Sens. 1 (H334) Skin Sens.1(H317) Repro. 2 (H361) Aq. Acute 3 (H402) Aq. Chronic 3 (H412)</td>
<td>0.5</td>
</tr>
<tr>
<td>Isotflupredone Acetate</td>
<td>338-98-7</td>
<td>206-423-9</td>
<td>Repr.Cat.3;R63</td>
<td>Repr. 2 (H361d)</td>
<td>0.1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>EU Classification</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lanolin</td>
<td>8006-54-0</td>
<td>232-348-6</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

Additional Information: * Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Rinse immediately with plenty of water, also under the eyelids, for at least 15 minutes. If irritation occurs or persists, get medical attention.

Skin Contact: Wash skin with soap and water. If irritation occurs or persists, get medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: No data available
Medical Conditions: None known
Aggravated by Exposure:

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE-FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters
6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures
Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions
Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up
Measures for Cleaning / Collecting:
Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Additional Consideration for Large Spills:
Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling
When handling, use appropriate personal protective equipment (see Section 8). Avoid contact with eyes, skin and clothing. Avoid breathing vapor or mist. Wash thoroughly after handling.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions:
Store as directed by product packaging.
Specific end use(s):
No data available

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters
Refer to available public information for specific member state Occupational Exposure Limits.

Mineral oil

ACGIH Threshold Limit Value (TWA) 5 mg/m³
Australia TWA 5 mg/m³
Belgium OEL - TWA 5 mg/m³
Bulgaria OEL - TWA 5.0 mg/m³
Czech Republic OEL - TWA 5 mg/m³
Denmark OEL - TWA 1 mg/m³
Finland OEL - TWA 5 mg/m³
Greece OEL - TWA 5 mg/m³
Lithuania OEL - TWA 1 mg/m³
Netherlands OEL - TWA 5 mg/m³
Vietnam OEL - TWAs 5 mg/m³
OSHA - Final PELS - TWAs: 5 mg/m³
Poland OEL - TWA 5 mg/m³
Portugal OEL - TWA 5 mg/m³
Romania OEL - TWA 5 mg/m³
Slovakia OEL - TWA 5 ppm
                     1 mg/m³
                     5 mg/m³
Spain OEL - TWA 5 mg/m³
Sweden OEL - TWAs 1 mg/m³
8. EXPOSURE CONTROLS / PERSONAL PROTECTION

<table>
<thead>
<tr>
<th>Material</th>
<th>Exposure Controls</th>
<th>Personal Protective Equipment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neomycin Sulfate</td>
<td>Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes.</td>
<td>Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).</td>
</tr>
<tr>
<td>Isoflupredone Acetate</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Hands:** Wear impervious gloves if skin contact is possible.

**Eyes:** Safety glasses or goggles

**Skin:** Use protective clothing (uniforms, lab coats, disposable coveralls, etc.) in both production and laboratory areas.

**Respiratory protection:** If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

<table>
<thead>
<tr>
<th>Physical State:</th>
<th>Ointment</th>
<th>Color: No data available.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Odor:</td>
<td>No data available.</td>
<td>Odor Threshold: No data available.</td>
</tr>
<tr>
<td>Molecular Formula:</td>
<td>Mixture</td>
<td>Molecular Weight: Mixture</td>
</tr>
<tr>
<td>Solvent Solubility:</td>
<td>No data available.</td>
<td></td>
</tr>
<tr>
<td>Water Solubility:</td>
<td>No data available.</td>
<td></td>
</tr>
<tr>
<td>pH:</td>
<td>No data available.</td>
<td></td>
</tr>
<tr>
<td>Melting/Freezing Point (°C):</td>
<td>No data available.</td>
<td></td>
</tr>
<tr>
<td>Boiling Point (°C):</td>
<td>No data available.</td>
<td></td>
</tr>
<tr>
<td>Partition Coefficient: (Method, pH, Endpoint, Value)</td>
<td>No data available.</td>
<td></td>
</tr>
<tr>
<td>Isoflupredone Acetate</td>
<td>Predicted 7.4 Log D 2.46</td>
<td></td>
</tr>
<tr>
<td>Neomycin Sulfate</td>
<td>Predicted 7.4 Log D 1.20</td>
<td>No data available.</td>
</tr>
<tr>
<td>Decomposition Temperature (°C):</td>
<td>No data available.</td>
<td></td>
</tr>
<tr>
<td>Evaporation Rate (Gram/s):</td>
<td>No data available.</td>
<td></td>
</tr>
<tr>
<td>Vapor Pressure (kPa):</td>
<td>No data available.</td>
<td></td>
</tr>
<tr>
<td>Vapor Density (g/ml):</td>
<td>No data available.</td>
<td></td>
</tr>
<tr>
<td>Relative Density:</td>
<td>No data available.</td>
<td></td>
</tr>
<tr>
<td>Viscosity:</td>
<td>No data available.</td>
<td></td>
</tr>
<tr>
<td>Flammability:</td>
<td>No data available.</td>
<td></td>
</tr>
<tr>
<td>Autoignition Temperature (Solid) (°C):</td>
<td>No data available.</td>
<td></td>
</tr>
<tr>
<td>Flammability (Solids):</td>
<td>No data available.</td>
<td></td>
</tr>
<tr>
<td>Flash Point (Liquid) (°C):</td>
<td>No data available.</td>
<td></td>
</tr>
<tr>
<td>Upper Explosive Limits (Liquid) (% by Vol.):</td>
<td>No data available.</td>
<td></td>
</tr>
<tr>
<td>Lower Explosive Limits (Liquid) (% by Vol.):</td>
<td>No data available.</td>
<td></td>
</tr>
</tbody>
</table>
10. STABILITY AND REACTIVITY

Reactivity: No data available
Chemical Stability: Stable under normal conditions of use.
Possibility of Hazardous Reactions
  Oxidizing Properties: No data available
  Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.
  Incompatible Materials: As a precautionary measure, keep away from strong oxidizers
  Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects
General Information: The information included in this section describes the potential hazards of the individual ingredients. Toxicological properties of the formulation have not been investigated.

Acute Toxicity: (Species, Route, End Point, Dose)

Tetracaine Hydrochloride
Mouse Oral LD 50 160 mg/kg
Rat Sub-tenon injection (eye) LD 50 23.5mg/kg
Rat Subcutaneous LD 50 24mg/kg

Isoflupredone Acetate
Mouse IP LD50 > 1000 mg/kg

Lanolin
Rat Oral LD50 >5000 mg/kg

Neomycin Sulfate
Rat Oral LD 50 2750 mg/kg
Mouse Oral LD 50 2880mg/kg
Mouse Intraperitoneal LD 50 116mg/kg
Rat Subcutaneous LD 50 633mg/kg
Mouse Subcutaneous LD 50 275mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Neomycin Sulfate
Skin Irritation Rabbit Moderate
Eye Irritation Rabbit Minimal
Skin Sensitization Positive

Mineral oil
Eye Irritation Rabbit Moderate
Skin Irritation Rabbit Mild
11. TOXICOLOGICAL INFORMATION

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

<table>
<thead>
<tr>
<th>Isoflupredone Acetate</th>
<th>21 Day(s) Rat Oral 10 mg/kg/day LOAEL Liver, Male reproductive system, Thymus</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>90 Day(s) Rat Oral 0.2 mg/kg/day NOAEL None identified</td>
</tr>
<tr>
<td>Neomycin Sulfate</td>
<td>6 Week(s) Dog Oral 100 mg/kg/day NOAEL No effects at maximum dose</td>
</tr>
<tr>
<td></td>
<td>3 Month(s) Guinea Pig Oral 10 mg/kg/day NOAEL No effects at maximum dose</td>
</tr>
<tr>
<td></td>
<td>3 Month(s) Dog Subcutaneous 20 mg/kg/day LOAEL Kidney</td>
</tr>
<tr>
<td></td>
<td>12 Month(s) Cat Oral 12 mg/kg/day NOAEL Blood forming organs</td>
</tr>
<tr>
<td></td>
<td>3 Month(s) Guinea Pig Subcutaneous 10 mg/kg/day LOAEL Kidney</td>
</tr>
</tbody>
</table>

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

<table>
<thead>
<tr>
<th>Isoflupredone Acetate</th>
<th>Embryo / Fetal Development Rat Oral 0.1 mg/kg/day NOAEL Maternal toxicity, Fetotoxicity, Not teratogenic</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2 Generation Reproductive Toxicity Rat Oral 1 mg/kg/day NOAEL Fetotoxicity</td>
</tr>
<tr>
<td>Reproductive &amp; Fertility Cow Intramuscular 20 mg/kg/day LOEL Fetotoxicity</td>
<td></td>
</tr>
<tr>
<td>Lanolin</td>
<td>Fertility and Embryonic Development Rabbit Oral 200 mg/kg/day LOAEL Maternal toxicity, Not teratogenic</td>
</tr>
<tr>
<td>Neomycin Sulfate</td>
<td>Reproductive &amp; Fertility Mouse Oral 4000 mg/L NOAEL No effects at maximum dose</td>
</tr>
<tr>
<td></td>
<td>2 Generation Reproductive Toxicity Rat Oral 25 mg/kg/day NOAEL Fetotoxicity</td>
</tr>
<tr>
<td></td>
<td>Prenatal &amp; Postnatal Development Rat Subcutaneous 6 mg/kg/day LOAEL Developmental toxicity</td>
</tr>
</tbody>
</table>

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

<table>
<thead>
<tr>
<th>Neomycin Sulfate</th>
<th>Bacterial Mutagenicity (Ames) <em>Salmonella, E. coli</em> Negative</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mammalian Cell Mutagenicity Chinese Hamster Ovary (CHO) cells Negative</td>
</tr>
<tr>
<td></td>
<td><em>In Vivo</em> Cytoanalytics Mouse Negative</td>
</tr>
<tr>
<td></td>
<td><em>In Vitro</em> Chromosome Aberration Human Lymphocytes Positive</td>
</tr>
</tbody>
</table>

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

| Neomycin Sulfate | 2 Year(s) Rat Oral 25 mg/kg/day NOAEL Not carcinogenic                                            |

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.
12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be avoided.

Toxicity:

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

**Neomycin Sulfate**

*Daphnia magna* (Water Flea) OECD EC50 48 Hours 68 mg/L  
*Salmo gairdneri* (Trout) OECD NOEC 96 Hours >1000 mg/L

Bacterial Inhibition: (Inoculum, Method, End Point, Result)

**Neomycin Sulfate**

Activated sludge OECD EC50 399 mg/L

Persistence and Degradability: No data available

Bio-accumulative Potential:

**Isoflupredone Acetate**

Predicted 7.4 Log D 2.46

**Neomycin Sulfate**

Predicted 7.4 Log D 1.20

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.
### 15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

**Canada - WHMIS: Classifications**

**WHMIS hazard class:**
- Class D, Division 2, Subdivision A
- Class D, Division 2, Subdivision B

This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

---

**White Petrolatum**

<table>
<thead>
<tr>
<th>Regulation</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>CERCLA/SARA 313 Emission reporting</td>
<td>Not Listed</td>
</tr>
<tr>
<td>California Proposition 65</td>
<td>Not Listed</td>
</tr>
<tr>
<td>Inventory - United States TSCA - Sect. 8(b)</td>
<td>Present</td>
</tr>
<tr>
<td>Australia (AICS):</td>
<td>Present</td>
</tr>
<tr>
<td>REACH - Carcinogens Category 2:</td>
<td>Present</td>
</tr>
<tr>
<td>EU EINECS/ELINCS List</td>
<td>232-373-2</td>
</tr>
</tbody>
</table>

**Mineral oil**

<table>
<thead>
<tr>
<th>Regulation</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>CERCLA/SARA 313 Emission reporting</td>
<td>Not Listed</td>
</tr>
<tr>
<td>California Proposition 65</td>
<td>Not Listed</td>
</tr>
<tr>
<td>Inventory - United States TSCA - Sect. 8(b)</td>
<td>Present</td>
</tr>
<tr>
<td>Australia (AICS):</td>
<td>Present</td>
</tr>
<tr>
<td>EU EINECS/ELINCS List</td>
<td>232-384-2</td>
</tr>
</tbody>
</table>

**Tetracaine Hydrochloride**

<table>
<thead>
<tr>
<th>Regulation</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>CERCLA/SARA 313 Emission reporting</td>
<td>Not Listed</td>
</tr>
<tr>
<td>California Proposition 65</td>
<td>Not Listed</td>
</tr>
<tr>
<td>Australia (AICS):</td>
<td>Present</td>
</tr>
<tr>
<td>EU EINECS/ELINCS List</td>
<td>205-248-5</td>
</tr>
</tbody>
</table>

**Neomycin Sulfate**

<table>
<thead>
<tr>
<th>Regulation</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>CERCLA/SARA 313 Emission reporting</td>
<td>Not Listed</td>
</tr>
<tr>
<td>California Proposition 65</td>
<td>developmental toxicity initial date 10/1/92 internal use</td>
</tr>
<tr>
<td>Inventory - United States TSCA - Sect. 8(b)</td>
<td>Present</td>
</tr>
<tr>
<td>Australia (AICS):</td>
<td>Present</td>
</tr>
<tr>
<td>EU EINECS/ELINCS List</td>
<td>215-773-1</td>
</tr>
</tbody>
</table>

**Isoflupredone Acetate**

<table>
<thead>
<tr>
<th>Regulation</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>CERCLA/SARA 313 Emission reporting</td>
<td>Not Listed</td>
</tr>
<tr>
<td>California Proposition 65</td>
<td>Not Listed</td>
</tr>
<tr>
<td>Australia (AICS):</td>
<td>Present</td>
</tr>
</tbody>
</table>
Text of R phrases and GHS Classification abbreviations mentioned in Section 3

H301 - Toxic if swallowed
H317 - May cause an allergic skin reaction
H334 - May cause allergy or asthma symptoms or breathing difficulties if inhaled
H350 - May cause cancer
H361 - Suspected of damaging fertility or the unborn child
H402 - Harmful to aquatic life
H412 - Harmful to aquatic life with long lasting effects

Carcinogenic: Category 2
Toxic to Reproduction: Category 3
T - Toxic
Xn - Harmful

R25 - Toxic if swallowed.
R45 - May cause cancer.
R63 - Possible risk of harm to the unborn child.
R42/43 - May cause sensitization by inhalation and skin contact.

Data Sources: The data contained in this MSDS may have been gathered from confidential internal sources, raw material suppliers, or from the published literature.

Reasons for Revision: Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 5 - Fire Fighting Measures. Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 11 - Toxicology Information. Updated Section 12 - Ecological Information. Updated Section 15 - Regulatory Information. Updated Section 16 - Other Information.

Prepared by: Toxicology and Hazard Communication
Zoetis Global Risk Management

Zoetis Inc. believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet